Definition Pharmacokinetics Small Molecule 
Collaborative Drug
JULY 28, 2025
Some of the most recent enhancements to the CDD Vault Curves add-on include the Pharmacokinetic (PK) IV and Oral curve fits. The AUC will be calculated automatically and available by clicking Customize Your Report and selecting ‘Area under the curve’ from the protocol readout definition section. Stay tuned for future Vault updates.
Drug Target Review
JULY 21, 2025
2 A raft of emerging therapeutic modalities sits at the centre of this boom, spanning advanced biologics, engineered platforms and next-generation small molecules. This protective barrier prevents more than 98 percent of small-molecule drugs and all macromolecular therapeutics 3 from accessing the brain.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
APRIL 7, 2025
4 The definition has since evolved and expanded to include molecular signatures of pharmacodynamics and therapeutic response. Novel mechanisms of action associated with CGTs naturally create dosing effects that apply in very different ways than with traditional small molecule pharmacotherapies. 21(10):3517. Rodrigues AD.
DrugBaron
FEBRUARY 7, 2022
Finding small molecule drugs is much harder than finding a needle in a haystack – discovering the right arrangement of atoms to bind precisely to a protein target to elicit a particular response is a problem of vast dimensionality. Yet the situation with small molecules is even worse.
Practical Cheminformatics
JANUARY 8, 2024
When given the prompt “Please estimate the binding affinity between the drug Afatinib and target EGFR”, GPT-4 suggested a docking study, which is definitely not a wise choice. These fingerprint bits then map to atom environments or bond paths, which often don’t correspond to widely accepted functional group definitions.
The Pharma Data
AUGUST 21, 2020
Novartis has agreed to contribute a carefully curated library of about 1300 small molecules with antiviral activity to the CARE project. We are also supporting the consortium’s preclinical safety and pharmacokinetics workstreams. I guess that’s the true definition of situational leadership.
Agency IQ
JULY 26, 2024
in equipment) for products that are more complex or aren’t as well-characterized, such as antibody drug conjugates or recombinant DNA products, will be considered higher risk than they would if the change was made to the production of standard, small molecule products. Any CMC changes (e.g.,
Expert insights. Personalized for you.
Let's personalize your content